Alterations of the myristoylated, alanine-rich C kinase substrate (MARCKS) in prefrontal cortex in schizophrenia

Schizophrenia Research

Volumn 154, Issue 1-3, 2014, Pages 36-41

  Pinner, Anita L ^a   Haroutunian, Vahram ^b   Meador Woodruff, James H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cytoskeleton; Dendritic dynamics; Myristoylation; Neurotransmission; Synaptic plasticity

Indexed keywords

MARCKS PROTEIN; PEPTIDES AND PROTEINS; PROTEIN N MYRISTOYLTRANSFERASE; PROTEIN NIP71; UNCLASSIFIED DRUG; HALOPERIDOL; HALOPERIDOL DECANOATE; MEMBRANE PROTEIN; MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE; N-MYRISTOYLTRANSFERASE INHIBITOR PROTEIN 71, HUMAN; NEUROLEPTIC AGENT; SIGNAL PEPTIDE; TUMOR PROTEIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MYRISTYLATION; NERVE CELL PLASTICITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; ISOMERISM; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

AGED; ANIMALS; ANTIPSYCHOTIC AGENTS; BLOTTING, WESTERN; DOWN-REGULATION; FEMALE; HALOPERIDOL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOMERISM; MALE; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PHOSPHORYLATION; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 84897029323     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.02.003     Document Type: Article

References (73)

1. Aderem A. The MARCKS brothers: a family of protein kinase C substrates. Cell 1992, 71(5):713-716.
2. Amaral M.D., Pozzo-Miller L. The dynamics of excitatory synapse formation on dendritic spines. Cellscience 2009, 5(4):19-25.
3. Aoto J., Martinelli D.C., Malenka R.C., Tabuchi K., Sudhof T.C. Presynaptic neurexin-3 alternative splicing trans-synaptically controls postsynaptic AMPA receptor trafficking. Cell 2013, 154(1):75-88.
4. Arbuzova A., Schmitz A.A., Vergeres G. Cross-talk unfolded: MARCKS proteins. Biochem. J. 2002, 362(Pt 1):1-12.
5. Arbuzova A., Wang J., Murray D., Jacob J., Cafiso D.S., McLaughlin S. Kinetics of interaction of the myristoylated alanine-rich C kinase substrate, membranes, and calmodulin. J. Biol. Chem. 1997, 272(43):27167-27177.
6. Arnsten A.F., Wang M.J., Paspalas C.D. Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. Neuron 2012, 76(1):223-239.
7. Bauer D.E., Haroutunian V., McCullumsmith R.E., Meador-Woodruff J.H. Expression of four housekeeping proteins in elderly patients with schizophrenia. J. Neural. Transm. 2009, 116(4):487-491.
8. Calabrese B., Halpain S. Essential role for the PKC target MARCKS in maintaining dendritic spine morphology. Neuron 2005, 48(1):77-90.
9. Chen X.W., Feng Y.Q., Hao C.J., Guo X.L., He X., Zhou Z.Y., Guo N., Huang H.P., Xiong W., Zheng H., Zuo P.L., Zhang C.X., Li W., Zhou Z. DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. J. Cell Biol. 2008, 181(5):791-801.
10. Duman R.S. Remodeling chromatin and synapses in depression. Nat. Med. 2013, 19(3):267.
11. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009, 35(3):528-548.
12. Fitzgerald P.J., Barkus C., Feyder M., Wiedholz L.M., Chen Y.C., Karlsson R.M., Machado-Vieira R., Graybeal C., Sharp T., Zarate C., Harvey-White J., Du J., Sprengel R., Gass P., Bannerman D., Holmes A. Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?. Neurobiol. Dis. 2010, 40(3):608-621.
13. Garey L. When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits. J. Anat. 2010, 217(4):324-333.
14. Gascon E., Vutskits L., Kiss J.Z. Polysialic acid-neural cell adhesion molecule in brain plasticity: from synapses to integration of new neurons. Brain Res. Rev. 2007, 56(1):101-118.
15. Gilabert-Juan J., Varea E., Guirado R., Blasco-Ibanez J.M., Crespo C., Nacher J. Alterations in the expression of PSA-NCAM and synaptic proteins in the dorsolateral prefrontal cortex of psychiatric disorder patients. Neurosci. Lett. 2012, 530(1):97-102.
16. Glahn D.C., Laird A.R., Ellison-Wright I., Thelen S.M., Robinson J.L., Lancaster J.L., Bullmore E., Fox P.T. Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol. Psychiatry 2008, 64(9):774-781.
17. Glausier J.R., Lewis D.A. Dendritic spine pathology in schizophrenia. Neuroscience 2013, 251:90-107.
18. Gomez-Climent M.A., Guirado R., Castillo-Gomez E., Varea E., Gutierrez-Mecinas M., Gilabert-Juan J., Garcia-Mompo C., Vidueira S., Sanchez-Mataredona D., Hernandez S., Blasco-Ibanez J.M., Crespo C., Rutishauser U., Schachner M., Nacher J. The polysialylated form of the neural cell adhesion molecule (PSA-NCAM) is expressed in a subpopulation of mature cortical interneurons characterized by reduced structural features and connectivity. Cereb. Cortex 2011, 21(5):1028-1041.
19. Graber S., Maiti S., Halpain S. Cathepsin B-like proteolysis and MARCKS degradation in sub-lethal NMDA-induced collapse of dendritic spines. Neuropharmacology 2004, 47(5):706-713.
20. Guirado R., Perez-Rando M., Sanchez-Matarredona D., Castillo-Gomez E., Liberia T., Rovira-Esteban L., Varea E., Crespo C., Blasco-Ibanez J.M., Nacher J. The dendritic spines of interneurons are dynamic structures influenced by PSA-NCAM expression. Cereb. Cortex 2013, 2013 June 17. [Epub ahead of print] http://dx.doi.org/10.1093/cercor/bht156.
21. Harte M.K., Bachus S.B., Reynolds G.P. Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. Schizophr. Res. 2005, 75(2-3):303-308.
22. Hartwig J.H., Thelen M., Rosen A., Janmey P.A., Nairn A.C., Aderem A. MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. Nature 1992, 356(6370):618-622.
23. Honea R.A., Meyer-Lindenberg A., Hobbs K.B., Pezawas L., Mattay V.S., Egan M.F., Verchinski B., Passingham R.E., Weinberger D.R., Callicott J.H. Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings. Biol. Psychiatry 2008, 63(5):465-474.
24. Horn G. Visual imprinting and the neural mechanisms of recognition memory. Trends Neurosci. 1998, 21(7):300-305.
25. Jentsch J.D., Trantham-Davidson H., Jairl C., Tinsley M., Cannon T.D., Lavin A. Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice. Neuropsychopharmacology 2009, 34(12):2601-2608.
26. Jia J.M., Zhao J., Hu Z., Lindberg D., Li Z. Age-dependent regulation of synaptic connections by dopamine D2 receptors. Nat. Neurosci. 2013, 16(11):1627-1636.
27. Kashihara K., Sato M., Fujiwara Y., Harada T., Ogawa T., Otsuki S. Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain. Biol. Psychiatry 1986, 21(7):650-656.
28. Kochlamazashvili G., Senkov O., Grebenyuk S., Robinson C., Xiao M.F., Stummeyer K., Gerardy-Schahn R., Engel A.K., Feig L., Semyanov A., Suppiramaniam V., Schachner M., Dityatev A. Neural cell adhesion molecule-associated polysialic acid regulates synaptic plasticity and learning by restraining the signaling through GluN2B-containing NMDA receptors. J. Neurosci. 2010, 30(11):4171-4183.
29. Le-Niculescu H., Levey D.F., Ayalew M., Palmer L., Gavrin L.M., Jain N., Winiger E., Bhosrekar S., Shankar G., Radel M., Bellanger E., Duckworth H., Olesek K., Vergo J., Schweitzer R., Yard M., Ballew A., Shekhar A., Sandusky G.E., Schork N.J., Kurian S.M., Salomon D.R., Niculescu A.B. Discovery and validation of blood biomarkers for suicidality. Mol. Psychiatry 2013, 18(12):1249-1264.
30. Leenders A.G., Sheng Z.H. Modulation of neurotransmitter release by the second messenger-activated protein kinases: implications for presynaptic plasticity. Pharmacol. Ther. 2005, 105(1):69-84.
31. Lenox R.H., McNamara R.K., Watterson J.M., Watson D.G. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain?. J. Clin. Psychiatry 1996, 57(Suppl. 13):23-31. (discussion 32-23).
32. Li H., Chen G., Zhou B., Duan S. Actin filament assembly by myristoylated alanine-rich C kinase substrate-phosphatidylinositol-4,5-diphosphate signaling is critical for dendrite branching. Mol. Biol. Cell 2008, 19(11):4804-4813.
33. Matus A. MARCKS for maintenance in dendritic spines. Neuron 2005, 48(1):4-5.
34. McLaughlin S., Aderem A. The myristoyl-electrostatic switch: a modulator of reversible protein-membrane interactions. Trends Biochem. Sci. 1995, 20(7):272-276.
35. McLaughlin S., Wang J., Gambhir A., Murray D. PIP(2) and proteins: interactions, organization, and information flow. Annu. Rev. Biophys. Biomol. Struct. 2002, 31:151-175.
36. McNamara R.K., Hussain R.J., Simon E.J., Stumpo D.J., Blackshear P.J., Abel T., Lenox R.H. Effect of myristoylated alanine-rich C kinase substrate (MARCKS) overexpression on hippocampus-dependent learning and hippocampal synaptic plasticity in MARCKS transgenic mice. Hippocampus 2005, 15(5):675-683.
37. McNamara R.K., Lenox R.H. Comparative distribution of myristoylated alanine-rich C kinase substrate (MARCKS) and F1/GAP-43 gene expression in the adult rat brain. J. Comp. Neurol. 1997, 379(1):48-71.
38. Murray D., Arbuzova A., Honig B., McLaughlin S. The role of electrostatic and nonpolar interactions in the association of peripheral proteins with membranes. Curr. Top. Membr. 2002, 52:277-307.
39. Murray D., Ben-Tal N., Honig B., McLaughlin S. Electrostatic interaction of myristoylated proteins with membranes: simple physics, complicated biology. Structure 1997, 5(8):985-989.
40. Northoff G., Waters H., Mooren I., Schluter U., Diekmann S., Falkai P., Bogerts B. Cortical sulcal enlargement in catatonic schizophrenia: a planimetric CT study. Psychiatry Res. 1999, 91(1):45-54.
41. Okuda H., Kuwahara R., Matsuzaki S., Miyata S., Kumamoto N., Hattori T., Shimizu S., Yamada K., Kawamoto K., Hashimoto R., Takeda M., Katayama T., Tohyama M. Dysbindin regulates the transcriptional level of myristoylated alanine-rich protein kinase C substrate via the interaction with NF-YB in mice brain. PLoS One 2010, 5(1):e8773.
42. Ouimet C.C., Wang J.K., Walaas S.I., Albert K.A., Greengard P. Localization of the MARCKS (87kDa) protein, a major specific substrate for protein kinase C, in rat brain. J. Neurosci. 1990, 10(5):1683-1698.
43. Pandey G.N., Dwivedi Y., Ren X., Rizavi H.S., Roberts R.C., Conley R.R., Tamminga C. Altered expression and phosphorylation of myristoylated alanine-rich C kinase substrate (MARCKS) in postmortem brain of suicide victims with or without depression. J. Psychiatr. Res. 2003, 37(5):421-432.
44. Pandey G.N., Dwivedi Y., SridharaRao J., Ren X., Janicak P.G., Sharma R. Protein kinase C and phospholipase C activity and expression of their specific isozymes is decreased and expression of MARCKS is increased in platelets of bipolar but not in unipolar patients. Neuropsychopharmacology 2002, 26(2):216-228.
45. Papaleo F., Yang F., Garcia S., Chen J., Lu B., Crawley J.N., Weinberger D.R. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol. Psychiatry 2012, 17(1):85-98.
46. Penzes P., Cahill M.E., Jones K.A., VanLeeuwen J.E., Woolfrey K.M. Dendritic spine pathology in neuropsychiatric disorders. Nat. Neurosci. 2011, 14(3):285-293.
47. Powchik P., Davidson M., Haroutunian V., Gabriel S.M., Purohit D.P., Perl D.P., Harvey P.D., Davis K.L. Postmortem studies in schizophrenia. Schizophr. Bull. 1998, 24(3):325-341.
48. Radau B., Otto A., Muller E.C., Westermann P. Protein kinase C alpha-dependent phosphorylation of Golgi proteins. Electrophoresis 2000, 21(13):2684-2687.
49. Ramakers G.M., McNamara R.K., Lenox R.H., De Graan P.N. Differential changes in the phosphorylation of the protein kinase C substrates myristoylated alanine-rich C kinase substrate and growth-associated protein-43/B-50 following Schaffer collateral long-term potentiation and long-term depression. J. Neurochem. 1999, 73(5):2175-2183.
50. Ramsden J.J., Vergeres G. Nonelectrostatic contributions to the binding of MARCKS-related protein to lipid bilayers. Arch. Biochem. Biophys. 1999, 371(2):241-245.
51. Rose S.D., Lejen T., Zhang L., Trifaro J.M. Chromaffin cell F-actin disassembly and potentiation of catecholamine release in response to protein kinase C activation by phorbol esters is mediated through myristoylated alanine-rich C kinase substrate phosphorylation. J. Biol. Chem. 2001, 276(39):36757-36763.
52. Rubio M.D., Haroutunian V., Meador-Woodruff J.H. Abnormalities of the Duo/Ras-related C3 botulinum toxin substrate 1/p21-activated kinase 1 pathway drive myosin light chain phosphorylation in frontal cortex in schizophrenia. Biol. Psychiatry 2012, 71(10):906-914.
53. Rutishauser U. Polysialic acid in the plasticity of the developing and adult vertebrate nervous system. Nat. Rev. Neurosci. 2008, 9(1):26-35.
54. Saggu S., Cannon T.D., Jentsch J.D., Lavin A. Potential molecular mechanisms for decreased synaptic glutamate release in dysbindin-1 mutant mice. Schizophr. Res. 2013, 146(1-3):254-263.
55. Sasaki Y. New aspects of neurotransmitter release and exocytosis: Rho-kinase-dependent myristoylated alanine-rich C-kinase substrate phosphorylation and regulation of neurofilament structure in neuronal cells. J. Pharmacol. Sci. 2003, 93(1):35-40.
56. Senkov O., Tikhobrazova O., Dityatev A. PSA-NCAM: synaptic functions mediated by its interactions with proteoglycans and glutamate receptors. Int. J. Biochem. Cell Biol. 2012, 44(4):591-595.
57. Seykora J.T., Myat M.M., Allen L.A., Ravetch J.V., Aderem A. Molecular determinants of the myristoyl-electrostatic switch of MARCKS. J. Biol. Chem. 1996, 271(31):18797-18802.
58. Sheu F.S., McCabe B.J., Horn G., Routtenberg A. Learning selectively increases protein kinase C substrate phosphorylation in specific regions of the chick brain. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(7):2705-2709.
59. Spizz G., Blackshear P.J. Overexpression of the myristoylated alanine-rich C-kinase substrate inhibits cell adhesion to extracellular matrix components. J. Biol. Chem. 2001, 276(34):32264-32273.
60. Stan A.D., Ghose S., Gao X.M., Roberts R.C., Lewis-Amezcua K., Hatanpaa K.J., Tamminga C.A. Human postmortem tissue: what quality markers matter?. Brain Res. 2006, 1123(1):1-11.
61. Stumpo D.J., Bock C.B., Tuttle J.S., Blackshear P.J. MARCKS deficiency in mice leads to abnormal brain development and perinatal death. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(4):944-948.
62. Szabo S.T., Machado-Vieira R., Yuan P., Wang Y., Wei Y., Falke C., Cirelli C., Tononi G., Manji H.K., Du J. Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology 2009, 56(1):47-55.
63. Tapp H., Al-Naggar I.M., Yarmola E.G., Harrison A., Shaw G., Edison A.S., Bubb M.R. MARCKS is a natively unfolded protein with an inaccessible actin-binding site: evidence for long-range intramolecular interactions. J. Biol. Chem. 2005, 280(11):9946-9956.
64. Theis T., Mishra B., von der Ohe M., Loers G., Prondzynski M., Pless O., Blackshear P.J., Schachner M., Kleene R. Functional role of the interaction between polysialic acid and myristoylated alanine-rich C kinase substrate at the plasma membrane. J. Biol. Chem. 2013, 288(9):6726-6742.
65. Trovo L., Ahmed T., Callaerts-Vegh Z., Buzzi A., Bagni C., Chuah M., Vandendriessche T., D'Hooge R., Balschun D., Dotti C.G. Low hippocampal PI(4,5)P(2) contributes to reduced cognition in old mice as a result of loss of MARCKS. Nat. Neurosci. 2013, 16(4):449-455.
66. Varea E., Guirado R., Gilabert-Juan J., Marti U., Castillo-Gomez E., Blasco-Ibanez J.M., Crespo C., Nacher J. Expression of PSA-NCAM and synaptic proteins in the amygdala of psychiatric disorder patients. J. Psychiatr. Res. 2012, 46(2):189-197.
67. Vergeres G., Manenti S., Weber T., Sturzinger C. The myristoyl moiety of myristoylated alanine-rich C kinase substrate (MARCKS) and MARCKS-related protein is embedded in the membrane. J. Biol. Chem. 1995, 270(34):19879-19887.
68. Walaas S.I., Sefland I. Modulation of calcium-evoked [3H]noradrenaline release from permeabilized cerebrocortical synaptosomes by the MARCKS protein, calmodulin and the actin cytoskeleton. Neurochem. Int. 2000, 36(7):581-593.
69. Wang J., Arbuzova A., Hangyas-Mihalyne G., McLaughlin S. The effector domain of myristoylated alanine-rich C kinase substrate binds strongly to phosphatidylinositol 4,5-bisphosphate. J. Biol. Chem. 2001, 276(7):5012-5019.
70. Wang J., Gambhir A., Hangyas-Mihalyne G., Murray D., Golebiewska U., McLaughlin S. Lateral sequestration of phosphatidylinositol 4,5-bisphosphate by the basic effector domain of myristoylated alanine-rich C kinase substrate is due to nonspecific electrostatic interactions. J. Biol. Chem. 2002, 277(37):34401-34412.
71. Wang J.K., Walaas S.I., Greengard P. Protein phosphorylation in nerve terminals: comparison of calcium/calmodulin-dependent and calcium/diacylglycerol-dependent systems. J. Neurosci. 1988, 8(1):281-288.
72. Watson D.G., Lenox R.H. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J. Neurochem. 1996, 67(2):767-777.
73. Yang H., Wang X., Sumners C., Raizada M.K. Obligatory role of protein kinase Cbeta and MARCKS in vesicular trafficking in living neurons. Hypertension 2002, 39(2 Pt 2):567-572.